Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 15, 2018

Primary Completion Date

April 11, 2024

Study Completion Date

April 11, 2024

Conditions
Kidney Transplant Rejection
Interventions
BIOLOGICAL

MDR-101

Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells

Trial Locations (19)

13210

Upstate University Hospital, Syracuse

19107

Thomas Jefferson University, Philadelphia

20007

Georgetown University Medical Center, Washington D.C.

22031

INOVA Fairfax Hospital, Fairfax

32224

Mayo Clinic Hospital, Jacksonville

44106

University Hospitals Cleveland Medical Center, Cleveland

53792

University of Wisconsin School of Medicine, Madison

55905

Mayo Clinic, Rochester

75246

Baylor University Medical Center, Dallas

77030

The Methodist Hospital, Houston

80045

University of Colorado Denver, Aurora

84107

Intermountain Transplant Center, Murray

90033

USC, Los Angeles

92354

Loma Linda University Medical Center, Loma Linda

94305

Stanford University Medical Center, Stanford

06519

Yale University, New Haven

60153-3328

Loyola University Medical Center, Maywood

07052

RWJBarnabas Health, Orange

H1T 2M4

CIUSSS de l'Est- de-l'Île-de-Montréal Installation Hopital Maisonneuve-Rosemont, Montreal

Sponsors
All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

Medeor Therapeutics, Inc.

INDUSTRY